0
0
NEW DELHI — Leading haematologists and public health advocates are calling for the urgent implementation of India-specific Standard Treatment Guidelines (STGs) for haemophilia, warning that a lack of uniform protocols is leaving nearly 80% of the country’s patients undiagnosed. This collective push, highlighted around World Haemophilia Day, seeks to transition the national care model from reactive, emergency-based treatment to a proactive, preventive approach known as prophylaxis. Experts argue that without these standards, the quality of life for tens of thousands of Indians remains dictated by their geography and income rather than medical necessity.
A Silent Crisis of Underdiagnosis
Haemophilia is an inherited genetic disorder that impairs the blood’s ability to clot. For those living with the condition, a simple stumble or a minor cut can escalate into prolonged internal bleeding. Most dangerously, spontaneous bleeds into joints and muscles can cause irreversible crippling, while intracranial hemorrhages can be fatal.
The scale of the challenge in India is immense. While the Haemophilia Federation of India has approximately 19,000 registered patients, epidemiological estimates suggest the true number of severe Haemophilia A cases lies between 80,000 and 100,000.
“Haemophilia A remains unacceptably underdiagnosed in India,” noted a 2024 expert opinion paper published in the peer-reviewed journal Cureus. This “care gap” means that for every patient receiving treatment, four others may be suffering in silence, unaware of their condition until a catastrophic medical event occurs.
The Push for Standardized Care
Currently, haemophilia management in India is fragmented. A patient treated at a premier institute in a metropolitan city may receive world-class care, while someone in a rural district might only receive “on-demand” treatment—clotting factor concentrates administered only after a bleed has already started.
Experts are advocating for Standard Treatment Guidelines (STGs) to harmonize care. These guidelines would provide a roadmap for doctors at all levels—from primary health centers to tertiary hospitals—covering:
-
Early Diagnosis: Standardized screening for children showing unusual bruising or joint swelling.
-
Factor Replacement: Clear protocols on the dosage and frequency of clotting factors.
-
Prophylaxis: Moving toward regular preventive infusions to stop bleeds before they happen.
-
Long-term Follow-up: Consistent monitoring of joint health and “inhibitor” development (antibodies that make treatment less effective).
Dr. Parul Bhatt, Professor and Head of Medicine at Gujarat Medical Education & Research Society, emphasizes that India must make prophylaxis the standard of care. This aligns with international guidance from the World Federation of Hemophilia (WFH), which recommends preventive treatment to preserve joint function and improve life expectancy.
The Resource Reality
While international standards are the goal, experts caution against a “one-size-fits-all” adoption of Western protocols. In high-income countries, 80% to 90% of patients receive prophylaxis; in India, that number hovers at a staggering 4%.
“Global guidance cannot simply be copied into India without accounting for local resource constraints,” says Dr. Joseph John, Professor and Head of Clinical Haematology at Christian Medical College, Ludhiana.
Because clotting factor concentrates are expensive and often require cold-chain storage, the proposed Indian guidelines may advocate for “low-dose prophylaxis.” Research suggests that even lower doses of preventive treatment are significantly more effective at preventing joint damage than treating bleeds after they occur, offering a cost-effective middle ground for the Indian healthcare system.
New Frontiers: Subcutaneous Therapy
The treatment landscape is also evolving with the introduction of non-factor therapies like emicizumab. Available in India since 2019, this monoclonal antibody is administered via a simple injection under the skin (subcutaneous), rather than the traditional, more difficult intravenous infusion.
According to the Cureus study, emicizumab represents a breakthrough for patients who live far from specialist centers or those who have developed inhibitors. However, specialists warn that these newer options are not a “set-and-forget” solution. Breakthrough bleeds can still occur, and the medication requires careful oversight to avoid complications when combined with other clotting agents.
Public Health Implications: The “Hidden” Costs
The lack of standardized haemophilia care carries a heavy economic burden. When a child suffers from repeated joint bleeds, they miss school, and their parents miss work. Over time, the child may develop permanent disabilities, requiring surgical interventions and lifelong support.
“Standardized guidance helps the entire ecosystem,” says a report from the Indian Council of Medical Research (ICMR). By identifying patients early and stabilizing them through STGs, the healthcare system can reduce the number of emergency room visits and expensive rehabilitative surgeries.
What This Means for Families
For the general public, the primary takeaway is awareness. Medical professionals advise looking for the following “red flags” in children and adults:
-
Unusual or excessive bleeding after minor injuries or dental work.
-
Large, deep bruises that appear without a clear cause.
-
Unexplained pain, swelling, or tightness in joints (knees, elbows, ankles).
-
Frequent, hard-to-stop nosebleeds.
If these symptoms are present, it is vital to consult a haematologist. For those already diagnosed, experts recommend discussing the feasibility of home-based therapy and regular joint screenings with their healthcare provider.
The Road Ahead
The journey toward universal haemophilia care in India is uphill, but the momentum for national guidelines marks a pivotal shift. As policy advocates and medical societies collaborate, the focus remains on ensuring that a patient’s survival and mobility are no longer determined by their pin code.
As the 2024 Cureus review concludes, the evidence is clear: haemophilia is a manageable condition, provided the system is designed to find the patients and treat them before the damage is done.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.ndtv.com/health/experts-urge-standard-treatment-guidelines-to-streamline-haemophilia-care-in-india-11372295
